P

Inventor

NITTOLI THOMAS

US40 patents
⚠️ This page may combine multiple inventors who share the name “NITTOLI THOMAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REGENERON PHARMA

38 patents
US10772972B2Sep 15, 2020

Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

REGENERON PHARMA44 citations97
US10738130B2Aug 11, 2020

Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof

REGENERON PHARMA50 citations97
US9302015B2Apr 5, 2016

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

REGENERON PHARMA82 citations97
US9950076B2Apr 24, 2018

Maytansinoid derivatives, conjugates thereof, and methods of use

REGENERON PHARMA34 citations94
US9951141B2Apr 24, 2018

Antibody-drug conjugates, their preparation and their therapeutic use

REGENERON PHARMA20 citations93
US9475875B2Oct 25, 2016

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMA14 citations92
US10570151B2Feb 25, 2020

Biologically active molecules, conjugates thereof, and therapeutic uses

REGENERON PHARMA12 citations86
US10463749B2Nov 5, 2019

Maytansinoid derivatives, conjugates thereof, and methods of use

REGENERON PHARMA4 citations84
US11485793B2Nov 1, 2022

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

REGENERON PHARMA4 citations83
US11142578B2Oct 12, 2021

Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof

REGENERON PHARMA6 citations83
US10941208B2Mar 9, 2021

Anti-MUC16 antibodies

REGENERON PHARMA6 citations83
US9545451B2Jan 17, 2017

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

REGENERON PHARMA6 citations83
US11446389B2Sep 20, 2022

Maytansinoid derivatives, conjugates thereof, and methods of use

REGENERON PHARMA1 citations73
US10738124B2Aug 11, 2020

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMA3 citations73
US11633501B2Apr 25, 2023

Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof

REGENERON PHARMA3 citations72
US10683354B2Jun 16, 2020

Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells

REGENERON PHARMA1 citations72
US10106616B2Oct 23, 2018

Antagonist antibodies to human prolactin receptor (PRLR)

REGENERON PHARMA2 citations72
US9688764B2Jun 27, 2017

Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies

REGENERON PHARMA3 citations72
US12545735B2Feb 10, 2026

Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof

REGENERON PHARMA0 citations62
US12419963B2Sep 23, 2025

Diels-Alder conjugation methods

REGENERON PHARMA0 citations62
US12378258B2Aug 5, 2025

Biologically active molecules, conjugates thereof, and therapeutic uses

REGENERON PHARMA0 citations62
US11866502B2Jan 9, 2024

Anti-FGFR2 antibodies and methods of use thereof

REGENERON PHARMA0 citations62
US11608380B2Mar 21, 2023

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMA0 citations62
US11345715B2May 31, 2022

Biologically active molecules, conjugates thereof, and therapeutic uses

REGENERON PHARMA0 citations62
US10047160B2Aug 14, 2018

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMA1 citations62
US12570764B2Mar 10, 2026

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

REGENERON PHARMA0 citations61
US12564640B2Mar 3, 2026

Protein-antiviral compound conjugates

REGENERON PHARMA0 citations61
US12497460B2Dec 16, 2025

Anti-MSR1 antibodies and methods of use thereof

REGENERON PHARMA0 citations61
US11752214B2Sep 12, 2023

Protein-antiviral compound conjugates

REGENERON PHARMA0 citations61
US11377502B2Jul 5, 2022

Anti-MSR1 antibodies and methods of use thereof

REGENERON PHARMA1 citations61
US12583939B2Mar 24, 2026

Bispecific antigen binding molecules that bind HER2, and methods of use thereof

REGENERON PHARMA0 citations60
US11958910B2Apr 16, 2024

Bispecific antigen binding molecules that bind HER2, and methods of use thereof

REGENERON PHARMA1 citations60
US12297207B2May 13, 2025

Maytansinoid derivatives, conjugates thereof, and methods of use

REGENERON PHARMA0 citations52
US11814428B2Nov 14, 2023

Anti-PTCRA antibody-drug conjugates and uses thereof

REGENERON PHARMA0 citations52
US10752690B2Aug 25, 2020

Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses

REGENERON PHARMA0 citations51
US10526344B2Jan 7, 2020

Amino acid acylation reagents and methods of using the same

REGENERON PHARMA0 citations46
US11596635B2Mar 7, 2023

Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses

REGENERON PHARMA0 citations44
US11666658B2Jun 6, 2023

Rifamycin analogs and antibody-drug conjugates thereof

REGENERON PHARMA0 citations38

UNIV PENNSYLVANIA

1 patent

REGENEREN PHARMACEUTICALS INC

1 patent